FDA
-
-
-
-
-
-
-
Galmed and Tissue Dynamics identify cardiac fibrosis pathway
-
-
-
-
-
-
-
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
-
-
-
-
-
-
-
Galmed receives South Korea patent for Aramchol-Rezdiffra combination
-
-
-
-
-
-
-
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
-
-
-
-
-
-
-
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
-
-
-
-
-
-
-
Galmed Pharma (GLMD) reports Results from Aramchol Phase 3 Open Label part
-
-
-
-
-
-
-
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

